Alamar Biosciences, Inc.
Research Alamar Biosciences, Inc. (ALMR) on Bullrun: market cap USD 1.75B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerALMR
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryMedical Devices
- CurrencyUSD
- Market capUSD 1.75B
- Financial periodQ2 2026
- RevenueUSD 29.43M
- Net income-USD 13.20M
- Free cash flow-USD 15.07M
- Gross margin60.2%
Valuation Snapshot
latest market cap is USD 1.75B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 74.21M | -USD 29.82M | -USD 59.99M | 56.2% | -0.45 | USD 30.00M | USD 41.47M | -USD 158.95M |
| FY2024 | USD 25.14M | -USD 47.07M | -USD 58.60M | 34.2% | -0.71 | USD 26.77M | USD 33.10M | -USD 133.41M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 1.75B | n/a | n/a | n/a |
About Alamar Biosciences, Inc.
Alamar Biosciences, Inc., a proteomics company, develops a proteomic liquid biopsy platform and sells instruments, consumables, and services to early detection of diseases. The company develops NULISA technology, a proteomics platform that detects and quantifies protein biomarkers.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Alamar Biosciences, Inc.'s market cap?
Alamar Biosciences, Inc.'s market capitalization is USD 1.75B.
What does Alamar Biosciences, Inc. do?
Alamar Biosciences, Inc., a proteomics company, develops a proteomic liquid biopsy platform and sells instruments, consumables, and services to early detection of diseases. The company develops NULISA technology, a proteomics platform that detects and quantifies protein biomarkers. It offers ARGO high throughput (HT) System, a fully automated precision proteomics platform, performs ultra-high sensitivity and multiplexed analysis to support biomarker analysis across the continuum of discovery, translational research and ultimately, and diagnostics.